Entry | Radiotracer | Biological target | Disease relevance | Reference(s) |
---|---|---|---|---|
1 |
| Y Y5 receptor | Weight loss | (Kealey et al. 2011) |
2 |
| D2 receptor | Movement disorders, schizophrenia | (Dahl et al. 2015b), (Rahman et al. 2015), (Andersen et al. 2015) |
3 |
| D2 receptor | Movement disorders, schizophrenia | (Dahl et al. 2015b) |
4 |
| TSPO | Neuroinflammation | (Rahman and Långström 2007) |
5 |
| CB1 | Neuropsychiatric disorders (e.g., schizophrenia, anxiety, and depression) | (Donohue et al. 2008) |
6 |
| mGluR1 | Anxiety, mood disorders, stroke, epilepsy, pain, and schizophrenia | (Hong et al. 2015) |
7 |
| HDAC6 | Neurodegenerative disorders and cancer | (Lu et al. 2016) |
8 |
| BACE-1 | Alzheimer’s disease | (Nordeman et al. 2014) |
9 |
| 5-HT1B | Migraine, depression, and anxiety | (Lindberg et al. 2019) |
10 |
| OGA | Alzheimer’s disease | a |
11 |
| H3R | Neuropsychiatric and neurodegenerative disorders | |
12 |
| H3R | Neuropsychiatric and neurodegenerative disorders | (Siméon et al. 2017) |
13 |
| Serine/threonine kinase | Melanomas | (Slobbe et al. 2017) |
14 |
| sHE | Inflammation and neuropathic pain | (Roslin et al. 2017) |
15 |
| TG2 | Celiac disease, cancer, fibrosis, and neurodegenerative diseases (e.g., Alzheimer’s, Huntington’s, Parkinson’s diseases) | (van der Wildt et al. 2016) |
16 |
| GAD | Neuropsychiatric disease (e.g., schizophrenia) | (Taddei et al. 2017b)b |
17 |
| cPLA2α | Oxidative stress and neuroinflammation | (Fisher et al. 2018) |
18 |
| Functionalized [11C]synthon for potential PET radiotracers (e.g., barbiturates) | (Barletta et al. 2006) | |
19 |
| AT2R | Prostate cancer and idiopathic pulmonary fibrosis | (Stevens et al. 2016) |
20 |
| Efflux transporter P-gp | Neurological disease (e.g., Alzheimer’s disease) | (Verbeek et al. 2012) |
21 |
| TKI | Cancer | (Poot et al. 2013) |
22 |
| 5-HT1B/1D | Locomotion and anxiety | (Lindhe et al. 2011) |